Innate Pharma to present phase 1 data for its IPH4502 ADC on November 18
In a press release published on November 11, 2026, the Marseille-based biotech stated that Professor Yohann Loriot (Gustave Roussy) will comment, alongside management, on the results presented at the EORTC-NCI-AACR (ENA) 2026 symposium. The company describes IPH4502 as the lead candidate in its proprietary portfolio focused on antibody-drug conjugates (ADCs).
Tolerability, Pharmacokinetics and Antitumor Activity of the Program
The event will be held on November 18, 2026 at 4 p.m. GMT (11 a.m. U.S. Eastern time) at the IET London, Savoy Place, both in person and remotely. It will include a review of the results of the dose-escalation study on the candidate's tolerability, pharmacokinetics and antitumor activity.
Discussions will also cover the current therapeutic landscape and the unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while management will present the scientific rationale for IPH4502 and the next steps in its clinical development.
A live question-and-answer session will follow the presentations, and a replay will be made available in the investor section of the company's website. Gustave Roussy will receive remuneration for the participation of its practitioner which, according to the press release, constitutes neither support for the experimental product nor a recommendation for its use.
Exatecan, Stable Linker and Proprietary Anti-Nectin-4 Antibody
IPH4502 is based on three components: exatecan, a topoisomerase I inhibitor, as the payload; a proprietary stable linker designed to slow the release of exatecan into circulation; and a humanized anti-Nectin-4 antibody whose epitope does not overlap with that of enfortumab vedotin. According to the company, exatecan could overcome certain limitations of MMAE-based ADCs.
Among these limitations are resistance linked to the MDR1 protein and the use of CYP2D6 genotyping. In preclinical studies, IPH4502 showed antitumor activity in models resistant to enfortumab vedotin and in tumors with low and heterogeneous Nectin-4 expression, which supports, according to Innate Pharma, a potential application beyond urothelial carcinoma.
The candidate is being evaluated in the phase 1 study IPH4502-101 (NCT06781983) in patients with advanced solid tumors expressing Nectin-4. It has not obtained marketing authorization in the European Union or from the FDA, and its efficacy and safety are not established for any commercial use.
